ProQR Therapeutics (PRQR) Accumulated Expenses (2014 - 2022)

ProQR Therapeutics (PRQR) has reported Accumulated Expenses for 9 consecutive years, with $9.9 million the latest figure, recorded in Q4 2022.

• Quarterly Accumulated Expenses fell 19.27% year-over-year to $9.9 million in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $9.9 million (down 19.27% YoY) and the FY2022 annual result came in at $9.9 million, down 19.27% from the prior year.
• Accumulated Expenses declined to $9.9 million in Q4 2022 per PRQR's latest filing, from $12.2 million in the prior quarter.
• Over the last five years, Accumulated Expenses for PRQR reached as high as $12.2 million in Q4 2021 and fell as low as $7.0 million in Q4 2020.
• A 5-year average of $9.5 million and a median of $9.9 million in 2022 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2020 — Accumulated Expenses slumped 30.57% — and 2021, when it jumped 75.87%.
• Year by year, Accumulated Expenses stood at $8.5 million in 2018, then advanced by 17.92% to $10.0 million in 2019, then sank by 30.57% to $7.0 million in 2020, then soared by 75.87% to $12.2 million in 2021, then dropped by 19.27% to $9.9 million in 2022.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $9.9 million, $12.2 million, and $7.0 million for Q4 2022, Q4 2021, and Q4 2020 respectively.